Hengrui Pharma

Hengrui Pharma accelerates bid for global brand status

The Chinese drugmaker has outlined plans for a secondary listing in Hong Kong to raise its international profile and bolster its overseas ambitions Key Takeaways: Hengrui Pharmaceuticals started out producing…
CSPC develops, produces and sells its own innovative drugs. Its growth has been sluggish over the past three years due to a slowdown for its finished drug business.

FAST NEWS: CSPC Pharma’s urticaria drug approved in China

The Latest: CSPC Pharmaceutical Group Ltd. (1093.HK) announced on Tuesday that its chronic spontaneous urticaria treatment, Omalizumab for Injection, has been approved for sale in China by the country’s National Medical Products Administration…
Liu Yongjun’s experience in the commercialization of innovative drugs and his connections with multinational pharmaceutical companies are urgently needed for CSPC Pharmaceutical’s ongoing transformation.

CSPC Pharma taps R&D superstar in quest for new breakout drugs

Liu Yongjun’s drug commercialization experience and ties to multinational firms are urgently needed for his new employer’s ongoing transformation Key Takeaways: CSPC Pharma’s new R&D head Liu Yongjun engineered the…
CSPC Pharma weighs up diet drug for bigger bottom line

CSPC Pharma weighs up diet drug for bigger bottom line

After three years of sluggish growth, the company has delivered higher quarterly earnings from sales of existing drugs and is exploring new avenues in the weight-loss business  Key Takeaways: CSPC…
The pharmaceutical company’s profits have been buffeted by erratic returns on an equity stake in a fellow developer of innovative drugs.

Profit setback for Simcere Pharma in novel drugs quest

The pharmaceutical company’s profits have been buffeted by erratic returns on an equity stake in a fellow developer of innovative drugs Key Takeaways: Simcere Pharmaceutical holds a 9% stake in…